{"schema_version":"secwatch.filing_event.v1","accession":"0001701478-26-000039","form_type":"8-K","ticker":"AZTR","cik":"0001701478","company_name":"Azitra, Inc.","filed_at":"2026-08-12T20:55:16+00:00","discovered_at":"2026-08-12T20:56:00.115475+00:00","generated_at":"2026-08-12T20:56:10.311836+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Azitra Q2 net loss widens to $3.3M; pauses ATR-12, advances ATR-COSF and ATR-04","bullets":["Net loss $3.3M in Q2 2026 vs $2.9M in Q2 2025; G&A up to $2.1M from $1.5M.","Cash and cash equivalents $6.7M as of June 30, 2026.","ATR-COSF: positive preclinical repeat-dose delivery and anti-wrinkle data in ex vivo human skin; proof-of-concept cosmetic study planned Q3 2026.","ATR-04: continuing Phase 1/2 enrollment (6 sites incl. MD Anderson); topline data from first cohort expected Q4 2026.","ATR-12 Netherton syndrome Phase 1b enrollment paused for capital allocation discipline."],"urls":{"canonical":"https://secwatch.observer/filing/0001701478-26-000039","json":"https://secwatch.observer/filing/0001701478-26-000039.json","markdown":"https://secwatch.observer/filing/0001701478-26-000039.md","text":"https://secwatch.observer/filing/0001701478-26-000039.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1701478/000170147826000039/0001701478-26-000039-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1701478/000170147826000039/aztr-20260812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-12T20:56:10.311836+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}